FdaApplication
NDA 210874
Identifiers
- fda_app_no: NDA210874
Properties
| Property | Value |
|---|---|
| applicant_name | ASTRAZENECA AB |
| application_type | NDA |
| approval_date | 2019-05-02 |
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| QTERNMET XR | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | 10MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| QTERNMET XR | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | 5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| QTERNMET XR | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | 2.5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL |
| QTERNMET XR | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE | 5MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL |
4 products